MSB2311 not checked

Transcenta Therapeutics (Hangzhou) Co., Ltd.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“An intravenous infusion with concentration from 10 mg/kg (Q3W)”In the company’s words, NCT03463473 on ClinicalTrials.gov
Tested for
Advanced Solid Tumors
Main trialPhase 1
“This is a phase I study to determine the safety and toxicity, PK/PD, immunogenicity, biomarkers, anti-tumor activity and establish a preliminary recommended Phase 2 dose (RP2D) in subjects with advanced solid tumors.”In the company’s words, NCT03463473 on ClinicalTrials.gov

Other drugs for Advanced Solid Tumors

All 2440 drugs for Advanced Solid Tumors

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials1

TrialPhaseCompletesWhat it tests
Phase 1Completed 1 Jun 2020 A Phase I Study of MSB2311 in Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow MSB2311

Following is part of Solo: you see every change to MSB2311 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in